These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14741034)

  • 1. Web-based tools for mining the NCI databases for anticancer drug discovery.
    Fang X; Shao L; Zhang H; Wang S
    J Chem Inf Comput Sci; 2004; 44(1):249-57. PubMed ID: 14741034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHMIS-C: a comprehensive herbal medicine information system for cancer.
    Fang X; Shao L; Zhang H; Wang S
    J Med Chem; 2005 Mar; 48(5):1481-8. PubMed ID: 15743190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
    Huang R; Wallqvist A; Covell DG
    J Med Chem; 2006 Mar; 49(6):1964-79. PubMed ID: 16539384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action.
    Huang R; Wallqvist A; Covell DG
    Biochem Pharmacol; 2005 Apr; 69(7):1009-39. PubMed ID: 15763539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data mining the NCI cancer cell line compound GI(50) values: identifying quinone subtypes effective against melanoma and leukemia cell classes.
    Marx KA; O'Neil P; Hoffman P; Ujwal ML
    J Chem Inf Comput Sci; 2003; 43(5):1652-67. PubMed ID: 14502500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
    Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data.
    Blower PE; Yang C; Fligner MA; Verducci JS; Yu L; Richman S; Weinstein JN
    Pharmacogenomics J; 2002; 2(4):259-71. PubMed ID: 12196914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical data mining of the NCI human tumor cell line database.
    Wang H; Klinginsmith J; Dong X; Lee AC; Guha R; Wu Y; Crippen GM; Wild DJ
    J Chem Inf Model; 2007; 47(6):2063-76. PubMed ID: 17915856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
    Huang R; Wallqvist A; Thanki N; Covell DG
    Pharmacogenomics J; 2005; 5(6):381-99. PubMed ID: 16103895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics.
    Yamori T
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S74-9. PubMed ID: 12819939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NCI's anticancer drug screening program may not be selecting for clinically active compounds.
    Brown JM
    Oncol Res; 1997; 9(5):213-5. PubMed ID: 9306428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PASS biological activity spectrum predictions in the enhanced open NCI database browser.
    Poroikov VV; Filimonov DA; Ihlenfeldt WD; Gloriozova TA; Lagunin AA; Borodina YV; Stepanchikova AV; Nicklaus MC
    J Chem Inf Comput Sci; 2003; 43(1):228-36. PubMed ID: 12546557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellipticinium acetate (CMEP) in breast cancer cells.
    Zhang M; Fang X; Liu H; Guo R; Wu X; Li B; Zhu F; Ling Y; Griffith BN; Wang S; Yang D
    Cancer Lett; 2007 Jul; 252(2):244-58. PubMed ID: 17293030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.
    Minig L; Trimble EL; Birrer MJ; Kim KY; Takebe N; Abrams JS
    Gynecol Oncol; 2010 Feb; 116(2):177-80. PubMed ID: 19889449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
    Christian MC; Pluda JM; Ho PT; Arbuck SG; Murgo AJ; Sausville EA
    Semin Oncol; 1997 Apr; 24(2):219-40. PubMed ID: 9129691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer drug development at the US National Cancer Institute.
    Takimoto CH
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors.
    Wallqvist A; Huang R; Covell DG
    J Chem Inf Model; 2007; 47(4):1414-27. PubMed ID: 17555311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemical evaluation by cancer cell line panel and its role in molecular target-based anticancer drug screening].
    Yamori T
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):485-90. PubMed ID: 15114687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDS.
    Weinstein JN; Myers T; Buolamwini J; Raghavan K; van Osdol W; Licht J; Viswanadhan VN; Kohn KW; Rubinstein LV; Koutsoukos AD
    Stem Cells; 1994 Jan; 12(1):13-22. PubMed ID: 8142917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.